Organization (Industry)
GLOBUS MEDICAL, INC.
ClinicalTrials.gov lists GLOBUS MEDICAL, INC. as lead sponsor of 17 trials, counting the companies grouped under it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. Companies grouped under this one are not included. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 1 registered with a 2026 start date. The dashed outline is the pace from the 1 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.4 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers GLOBUS MEDICAL, INC. and 1 company grouped under it: 17 lead-sponsored trials (16 its own, 1 in the grouped companies) and 3 legal-entity registrations (3 its own, 0 in the grouped companies).
Companies grouped under this page (1)
| Company | Lead trials | Legal entities |
|---|---|---|
| KB Medical SA | 1 | 0 |
Disease areas (11)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Intervertebral Disc Degeneration | 5 |
| Pain | 4 |
| Back Pain | 3 |
| Kyphosis | 2 |
| Low Back Pain | 2 |
Showing 5 of 11 disease areas.
Trials by start year as sponsor or collaborator (14)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2024 | 1 |
| 2019 | 2 |
| 2018 | 3 |
| 2017 | 1 |
| 2016 | 1 |
| 2014 | 1 |
| 2013 | 1 |
| 2012 | 2 |
| 2011 | 1 |
Showing 10 of 14 years.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 1 of 4 hit target (n=4) | 2 of 3 on time (n=3) |
Journals published in (21)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Spine | 14 |
| American journal of physical medicine & rehabilitation | 1 |
| Anesthesiology | 1 |
| Archives of physical medicine and rehabilitation | 1 |
| British medical bulletin | 1 |
Showing 5 of 21 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 1,935 | 797 | 2025-12-30 |
SEC-reported annual financials (11)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2025 | 2,938,931,000 | 537,868,000 | 147,246,000 |
| 2024 | 2,519,355,000 | 102,984,000 | 163,754,000 |
| 2023 | 1,568,476,000 | 122,873,000 | 124,010,000 |
| 2022 | 1,022,843,000 | 190,169,000 | 73,015,000 |
| 2021 | 958,102,000 | 149,191,000 | 97,346,000 |
| 2020 | 789,042,000 | 102,285,000 | 84,519,000 |
| 2019 | 785,368,000 | 155,210,000 | 60,073,000 |
| 2018 | 712,969,000 | 156,474,000 | 55,496,000 |
| 2017 | 635,977,000 | 107,348,000 | 43,679,000 |
| 2016 | 563,994,000 | 104,341,000 | 44,532,000 |
Showing 10 of 11 fiscal years.
Financing and grant events (12)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2025-05-15 | Other financing | not disclosed | Sec extracted |
| 2025-04-03 | Other financing | not disclosed | Sec extracted |
| 2023-09-27 | Debt financing | 400,000,000 | Sec extracted |
| 2023-04-27 | Other financing | not disclosed | Sec extracted |
| 2023-03-28 | Other financing | not disclosed | Edgar offerings |
Showing 5 of 12 events.
FDA warning letters (1)
| Issue date | Letter |
|---|---|
| 2024-07-15 | globus-medical-inc-685606-07152024 |
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| VAI | 22 |
FDA recalls (29)
Shown in this order: most recent first.
| Product | Classification | Initiated |
|---|---|---|
| MAGEC 2 Rod, 5.0mm 90mm Standard; Version/Model: MC2-5090S; | Class II | 2025-04-03 |
| ExcelsiusGPS Cannula A, 9mm x 250mm, Cannula used with ball tip probes, Model No. 6143.2844 | Class II | 2023-12-15 |
| Globus Medical Cranial Drill with Stop, 2.40mm - Instruments for access, preparation, and placement of cranial devices with the ExcelsiusGPS. Ref : 6143.1834S | Class II | 2023-12-11 |
| Globus Medical Cranial Drill with Stop, 3.20mm - instruments for access, preparation, and placement of cranial devices with the ExcelsiusGPS. Ref: 6143.1842S | Class II | 2023-12-11 |
| Globus Medical Cranial Drill, 6.00mm - instruments for access, preparation, and placement of cranial devices with the ExcelsiusGPS. Ref: 6143.1870S | Class II | 2023-12-11 |
Showing 5 of 29 recalls.
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 1 | 2024-11-14 |
Manufacturing and distribution sites (3)
Shown in this order: severity rank then name.
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| GLOBUS MEDICAL, INC. | AUDUBON, US | FDA | |
| GLOBUS MEDICAL, INC. | Methuen, US | FDA | |
| GLOBUS MEDICAL, INC. | Memphis, US | FDA |
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | not disclosed |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | not disclosed | not disclosed |
Latest dated events (2,018)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-06-15 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-12-30 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-12-30 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-12-23 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-12-23 | Patent granted | Granted US patents (PatentsView / USPTO) |
Showing 5 of 2,018 events.
Biomarker capability evidence (2)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| IDE | Trial sponsor | Named in trial inclusion criteria |
| IDE | Trial sponsor | Mentioned in trial text |
Not on this page
Checked, with nothing recorded for this organization: related companies not grouped here, active development programs, approved assets, fda untitled letters, organization relationships, clia clinical laboratory certificates, and biomarkers this organization publishes on.